Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
A phase 2 trial of Acalabrutinib, Rituximab in diffuse large b-cell lymphoma, run by AstraZeneca, now recruiting.
Overview
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL is a phase 2 interventional study registered as NCT05952024 by AstraZeneca, with 80 participants planned, started 2024-07-16 and due to reach its primary completion in 2029-04-22. Interventions recorded: Acalabrutinib, Rituximab. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Shares Acalabrutinib, Rituximab, AstraZeneca, Diffuse large B-cell lymphoma.
- TrialStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialStudy of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Shares Acalabrutinib, AstraZeneca.
- TrialA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Shares Acalabrutinib, AstraZeneca.